Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLY-230 dose-ranging study in healthy and diabetic subjects
NCT00544934Phase 2Completed
- Sponsor
- Glycadia Pharmaceuticals
- Start
- Feb 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of GLY-230 in diabetic nephropathy (DN), sponsored by Glycadia Pharmaceuticals. Started Feb 2007; status: completed.
02
Drugs
GLY-230
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00544934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00544934.